Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FENC Adherex Technologies	$7.76 -1.3%	$6.95	$3.96 ▼ $8.72	$216.94M	0.4	95,279 shs	76,976 shs
LENZ LENZ Therapeutics	$29.94 -0.3%	$27.93	$16.28 ▼ $38.93	$845.23M	0.42	192,953 shs	565,952 shs
REPL Replimune Group	$9.27 -2.3%	$8.83	$6.44 ▼ $17.00	$731.55M	0.63	889,871 shs	1.43 million shs
VIR Vir Biotechnology	$5.23 +0.4%	$5.30	$4.32 ▼ $14.45	$720.22M	1.24	1.38 million shs	2.95 million shs

A Beginner's Guide to Investing in Cannabis

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FENC Adherex Technologies	-1.27%	-2.14%	-6.39%	+16.34%	+16.69%
LENZ LENZ Therapeutics	-0.30%	+3.24%	+6.32%	+13.02%	+63.43%
REPL Replimune Group	-2.32%	-5.21%	+9.57%	-14.33%	+21.34%
VIR Vir Biotechnology	+0.38%	+0.19%	+15.96%	-24.53%	-41.56%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
FENC Adherex Technologies	1.9203 of 5 stars	3.6	2.0	0.0	0.0	3.3	0.0
LENZ LENZ Therapeutics	1.3567 of 5 stars	3.6	1.0	0.0	1.5	0.8	0.0
REPL Replimune Group	4.4038 of 5 stars	3.6	3.0	4.5	2.6	2.5	0.6
VIR Vir Biotechnology	2.3506 of 5 stars	3.4	1.0	0.0	0.6	3.3	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
FENC Adherex Technologies	3.25	Buy	$13.00	67.53% Upside
LENZ LENZ Therapeutics	3.17	Buy	$46.60	55.64% Upside
REPL Replimune Group	3.13	Buy	$20.83	124.74% Upside
VIR Vir Biotechnology	2.86	Moderate Buy	$32.86	528.24% Upside

Current Analyst Ratings Breakdown

Latest FENC, LENZ, REPL, and VIR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/20/2025	REPL Replimune Group	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight
6/2/2025	REPL Replimune Group	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$14.00 ➝ $22.00
5/22/2025	VIR Vir Biotechnology	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$14.00 ➝ $14.00
5/20/2025	FENC Adherex Technologies	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00 ➝ $13.00
5/14/2025	FENC Adherex Technologies	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$12.00 ➝ $13.00
5/12/2025	VIR Vir Biotechnology	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$19.00 ➝ $14.00
5/8/2025	LENZ LENZ Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$38.00 ➝ $38.00
4/17/2025	VIR Vir Biotechnology	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$28.00 ➝ $21.00
4/16/2025	LENZ LENZ Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$38.00 ➝ $38.00
4/14/2025	LENZ LENZ Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight ➝ Overweight	$38.00 ➝ $51.00

(Data available from 6/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
FENC Adherex Technologies	$47.54M	4.51	$0.03 per share	243.38	($0.21) per share	-36.95
LENZ LENZ Therapeutics	N/A	N/A	N/A	N/A	$7.42 per share	N/A
REPL Replimune Group	N/A	N/A	N/A	N/A	$5.40 per share	N/A
VIR Vir Biotechnology	$74.21M	9.74	N/A	N/A	$8.35 per share	0.63

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
FENC Adherex Technologies	-$440K	-$0.51	N/A	N/A	N/A	-45.52%	N/A	-26.37%	8/12/2025 (Estimated)
LENZ LENZ Therapeutics	-$49.77M	-$1.77	N/A	N/A	N/A	N/A	-23.74%	-22.65%	8/13/2025 (Estimated)
REPL Replimune Group	-$247.30M	-$3.07	N/A	N/A	N/A	N/A	-57.98%	-45.21%	8/6/2025 (Estimated)
VIR Vir Biotechnology	-$521.96M	-$4.22	N/A	N/A	N/A	-2,769.04%	-47.46%	-39.33%	7/30/2025 (Estimated)

Latest FENC, LENZ, REPL, and VIR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/22/2025	Q4 2025	REPL Replimune Group	-$0.75	-$0.82	-$0.07	-$0.82	N/A	N/A
5/13/2025	Q1 2025	FENC Adherex Technologies	-$0.12	-$0.04	+$0.08	-$0.04	$8.18 million	$8.51 million
5/7/2025	Q1 2025	LENZ LENZ Therapeutics	-$0.55	-$0.53	+$0.02	-$0.53	N/A	N/A
5/7/2025	Q1 2025	VIR Vir Biotechnology	-$0.83	-$0.88	-$0.05	-$0.88	$8.59 million	$3.03 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
FENC Adherex Technologies	N/A	N/A	N/A	N/A	N/A
LENZ LENZ Therapeutics	N/A	N/A	N/A	N/A	N/A
REPL Replimune Group	N/A	N/A	N/A	N/A	N/A
VIR Vir Biotechnology	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
FENC Adherex Technologies	N/A	5.13	4.97
LENZ LENZ Therapeutics	N/A	23.09	23.09
REPL Replimune Group	0.17	7.95	7.95
VIR Vir Biotechnology	N/A	6.79	6.79

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
FENC Adherex Technologies	55.51%
LENZ LENZ Therapeutics	54.32%
REPL Replimune Group	92.53%
VIR Vir Biotechnology	65.32%

Insider Ownership

Company	Insider Ownership
FENC Adherex Technologies	11.76%
LENZ LENZ Therapeutics	6.90%
REPL Replimune Group	8.80%
VIR Vir Biotechnology	16.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
FENC Adherex Technologies	N/A	27.60 million	24.35 million	Optionable
LENZ LENZ Therapeutics	110	28.15 million	26.20 million	N/A
REPL Replimune Group	210	77.09 million	70.30 million	Optionable
VIR Vir Biotechnology	580	138.24 million	116.12 million	Optionable

FENC, LENZ, REPL, and VIR Headlines

Recent News About These Companies

Brokerages Set Vir Biotechnology, Inc. (NASDAQ:VIR) Target Price at $32.86

June 17, 2025 | americanbankingnews.com

Vir Biotechnology, Inc. (NASDAQ:VIR) Given Consensus Rating of "Moderate Buy" by Brokerages

June 12, 2025 | marketbeat.com

Bank of America Corp DE Has $1.42 Million Stake in Vir Biotechnology, Inc. (NASDAQ:VIR)

June 6, 2025 | marketbeat.com

Insider Selling: Vir Biotechnology, Inc. (NASDAQ:VIR) Director Sells 3,200 Shares of Stock

June 3, 2025 | marketbeat.com

Janet Napolitano Sells 3,200 Shares of Vir Biotechnology, Inc. (NASDAQ:VIR) Stock

June 3, 2025 | insidertrades.com

Nuveen Asset Management LLC Has $2.64 Million Holdings in Vir Biotechnology, Inc. (NASDAQ:VIR)

June 3, 2025 | marketbeat.com

Vir Biotechnology (NASDAQ:VIR) Stock Price Down 7.6% - Here's What Happened

May 31, 2025 | marketbeat.com

Vir Biotechnology (NASDAQ:VIR) Trading 6.6% Higher - What's Next?

May 30, 2025 | marketbeat.com

Vir Biotech at TD Cowen’s Summit: Strategic Focus on HDV and Oncology

May 29, 2025 | investing.com

Vir Biotechnology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025

May 28, 2025 | businesswire.com

Voloridge Investment Management LLC Lowers Stock Position in Vir Biotechnology, Inc. (NASDAQ:VIR)

May 28, 2025 | marketbeat.com

Woodline Partners LP Makes New $991,000 Investment in Vir Biotechnology, Inc. (NASDAQ:VIR)

May 28, 2025 | marketbeat.com

Millennium Management LLC Has $12.59 Million Stock Position in Vir Biotechnology, Inc. (NASDAQ:VIR)

May 26, 2025 | marketbeat.com

Vir Biotechnology's (VIR) Buy Rating Reaffirmed at Needham & Company LLC

May 24, 2025 | marketbeat.com

HC Wainwright Has Optimistic Outlook of VIR Q2 Earnings

May 24, 2025 | marketbeat.com

Gilead pays partner Hookipa $10M to take over HBV, HIV therapeutic vaccine programs

May 22, 2025 | fiercebiotech.com

Vir Biotechnology Stock: A Deep Dive Into Analyst Perspectives (6 Ratings)

May 22, 2025 | benzinga.com

Point72 Asset Management L.P. Raises Stock Holdings in Vir Biotechnology, Inc. (NASDAQ:VIR)

May 22, 2025 | marketbeat.com

Vir Biotechnology, Inc. (NASDAQ:VIR) Shares Sold by D. E. Shaw & Co. Inc.

May 21, 2025 | marketbeat.com

Vir’s hepatitis B combo falls short in Phase II trial

May 12, 2025 | msn.com

Vir Biotechnology to Participate in Bank of America Securities 2025 Healthcare Conference

May 12, 2025 | businesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

FENC, LENZ, REPL, and VIR Company Descriptions

Adherex Technologies NASDAQ:FENC

$7.76 -0.10 (-1.27%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$7.81 +0.05 (+0.64%)

As of 06/20/2025 04:04 PM Eastern

Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.

LENZ Therapeutics NASDAQ:LENZ

$29.94 -0.09 (-0.30%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$29.92 -0.03 (-0.08%)

As of 06/20/2025 07:47 PM Eastern

LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.

Replimune Group NASDAQ:REPL

$9.27 -0.22 (-2.32%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$9.26 -0.01 (-0.16%)

As of 06/20/2025 07:11 PM Eastern

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

Vir Biotechnology NASDAQ:VIR

$5.23 +0.02 (+0.38%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$5.20 -0.03 (-0.48%)

As of 06/20/2025 05:44 PM Eastern

Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time